gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations

November 2018 Volume 4 – Lung Cancer

In January 2018, the FDA approved Gilotrif (afatinib; from Boehringer Ingelheim) for use as the first treatment in patients with metastatic non–small-cell lung cancer (NSCLC) associated with non-resistant EGFR mutations, as identified by an FDA-approved test.

Gilotrif is a second-generation tyrosine kinase inhibitor that was previously approved for patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, and for metastatic, squamous NSCLC that progressed with platinum-based chemotherapy.

This new indication for Gilotrif was based on durable responses in patients with metastatic NSCLC and nonresistant EGFR mutations other than exon 19 deletions or exon 21 L858R substitutions.

Overall, 66% of patients responded to treatment with Gilotrif. Among the 21 patients who responded to treatment, the response lasted 12 months or longer in half of the patients and 18 months or longer in one-third of patients.

The most common side effects with Gilotrif are diarrhea, rash, paronychia, dry skin, decreased appetite, nausea, vomiting, and pruritus.

Recommended For You
Lung Cancer
Drugs for Lung Cancer
Here are the drugs and financial support services available to patients receiving treatment for Lung Cancer.
Genetics & CancerLung CancerPatient Stories
Using My Lung Cancer Story to Advocate for Change in Minority Communities
By Brandi Bryant
After getting tested for genetic abnormalities, Brandi Bryant learned she had the ALK genetic mutation, which increases the risk for lung cancer. This information resulted in important changes in her treatment and led her to become an advocate for genetic testing, especially among minority communities.
Lung Cancer
Tecentriq plus Chemotherapy Approved as First Therapy for Metastatic Lung Cancer without EGFR or ALK Mutations
Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer.
Lung Cancer
What Do I Need to Know? A Guide for the Newly Diagnosed Person with Lung Cancer
By Claudia T Miller, BSN, RN, OCN, ONN-CG
The treatment landscape of lung cancer has changed dramatically in the past 5 years. New immunotherapies have significantly improved survival. Learn about your diagnosis and the current treatment options.
Last modified: December 11, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country